" An independent monitoring board has given Merck & Co the go-ahead to recruit more people for late-stage BACE inhibitor trials. "
Alzheimer’s drug enters Phase III after safety trial

An independent monitoring board has given pharmaceutical company Merck & Co the go-ahead to recruit more people for two late-stage trials of its experimental Alzheimer’s drug, known as BACE inhibitors.

The medicine works by blocking beta secretase the enzyme involved in production of beta-amyloid, a protein that creates brain plaques considered a major cause of the progressive disease.

You can read more about the trial at Reuters.

 Posted: December 13th, 2013
Discussion

No discussion yet.

Add a comment:

Call the National Dementia Helpline: 1800 100 500